BioMarin Pharmaceutical Story

BioMarin Pharmaceutical Inc -- USA Stock  

USD 89.64  0.6  0.66%

Macroaxis does not monitor all media channels or aggregates social signals for BioMarin Pharmaceutical. But even though we do not provide professional-grade financial sentiment analysis on BioMarin Pharmaceutical, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for BioMarin Pharmaceutical. Check also BioMarin Pharmaceutical Hype Analysis, BioMarin Pharmaceutical Correlation and BioMarin Pharmaceutical Performance
Bona fide gift to Robert Baffi of 2675 shares of BioMarin Pharmaceutical subject to Section 16
Filed transaction by Biomarin Pharmaceutical I officer. Exempt bona fide gift subject to Rule 16b-3

BioMarin Pharmaceutical Inc insider trading alert for gift of common stock by Robert Baffi, EVP Technical Operations, on January 3, 2018. This event was filed by Biomarin Pharmaceutical I with SEC on 2016-03-07. Statement of changes in beneficial ownership - SEC Form 4. Robert Baffi is currently serves as executive vp of technical operations of BioMarin Pharmaceutical

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.91% . The overall trading delta when the story was published against the current closing price is 1.43% .

Similar stores for BioMarin Pharmaceutical

few hours ago at http://standardoracle.com 
Revenue Estimates of the Stock BioMarin Pharmaceutical Inc. , The ...
news
BioMarin Pharmaceutical Inc. shares jumped 0.02 percent and closed the day at 90.24. The company has its outstanding shares of 175.72 Million.
few days ago at www.macroaxis.com 
Exercise or conversion by Bienaime Jean Jacques of 5000 shares of BioMarin Pharmaceutical subject to Rule 16b-...
Macroaxis News
Filed transaction by Biomarin Pharmaceutical I director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at www.macroaxis.com 
Exercise or conversion by Bienaime Jean Jacques of 10000 shares of BioMarin Pharmaceutical subject to Rule 16b...
Macroaxis News
Filed transaction by Biomarin Pharmaceutical I director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at http://postanalyst.com 
Exercise or conversion by V Lawlis of 3750 shares of BioMarin Pharmaceutical subject to Rule 16b-3
news
Filed transaction by Biomarin Pharmaceutical I director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Did you try this?

Run Chance of Distress Now
   

Chance of Distress

Get analysis of equity chance of financial distress in the next 2 years
Hide  View All  NextLaunch Chance of Distress

Beta

Beta Comparative Analysis
  Beta 
      BioMarin Pharmaceutical Comparables 
BioMarin Pharmaceutical is currently under evaluation in beta category among related companies. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of financial instrument to the financial market in which this instrument is traded. For example if Beta of equity is 2, it will be expected to significantly outperform market when market is going up and significantly underperform when market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns during over time.